This program has concluded. Thank you for attending. Please select "Next Page" to proceed to the posttest, evaluation, and credit pages.
To obtain your CME/CE credit:
Within 48 hours ofthe program's completion, you will receive an email with a link to take the posttest, complete the evaluation, and claim your credit.
Note for ODs: COPE guidelines dictate that in order to receive credit, you must view the program within its required instructional time.
This activity is designed to bring U.S. optometrists and ophthalmologists together to study and discuss new technologies and practices in the diagnosis and treatment of glaucoma. This meeting will provide for the exchange of ideas between leading scientists and physicians.
This activity is supported by unrestricted educational grants from AbbVie, Carl Zeiss Meditec, Glaukos, Heidelberg Engineering, New World Medical, Ora, Inc, Qlaris Bio, and Santen.
Upon completion of this activity, the participant should be able to:
Jointly provided by Evolve Medical Education and The Glaucoma Foundation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Glaucoma Foundation. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evolve Medical Education, LLC is a COPE-accredited administrator.
This live activity, COPE Activity Number 124893, is accredited by COPE for continuing education for optometrists for 4.5 hours.
Course #: 81193-GL
Activity #: 124893
This virtual activity, COPE Activity Number 124895, is accredited by COPE for continuing education for optometrists for 4.5 hours.
Course #: 81291-GL
Activity #: 124895
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Vincent Michael Patella, OD, FAAO
Adjunct Assistant Professor
Department of Ophthalmology
University of Iowa
Iowa City, IA
Lucy Qing Shen, MD
Director, Glaucoma Fellowship, Massachusetts Eye and Ear
Associate Professor of Ophthalmology
Harvard Medical School
Boston, MA
Murray Fingeret, OD, FAAO
Clinical Professor of Optometry
State University of New York
College of Optometry
New York, NY
Janey L. Wiggs, MD, PhD
Paul Austin Chandler
Professor of Ophthalmology
Co-Director, Glaucoma Center of Excellence Vice Chair, Clinical Research
Associate Director, Ocular Genomics Institute Harvard Medical School
Associate Director, Howe Laboratory
Associate Chief
Ophthalmology Clinical Research
Senior Scientist Mass. Eye and Ear
Boston, MA
Gregory K. Harmon, MD
Chair, Advisory Board
The Glaucoma Foundation
Cataract & Glaucoma Surgeon, NYC
Clinical Associate Professor of Ophthalmology,
Weill Medical College of Cornell University,
New York Presbyterian Hospital
Associate Adjunct Surgeon,
New York Eye & Ear Infirmary, Mount Sinai
New York, NY
Linda Zangwill, PhD
Professor of Ophthalmology in Residence
Richard K. Lansche M.D. and Tatiana A. Lansche Endowed Chair
Co-Director of Clinical Research
Hamilton Glaucoma Center
Director, Hamilton Glaucoma Center
Data Coordinating Center
University of California, San Diego
San Diego, CA
Louis Pasquale MD, FARVO
Co-Chairman, Scientific Advisory Board
The Glaucoma Foundation
Shelley and Steven Einhorn Distinguished Professor of Ophthalmology
Site Chair, Department of Ophthalmology,
Mount Sinai Hospital Vice Chair,
Translational Ophthalmology Research
Mount Sinai Healthcare System
New York, NY
Jeffrey M. Liebmann, MD
Professor of Ophthalmology, Glaucoma Service Director, and Vice-Chair for the Department of Ophthalmology at Columbia University Medical Center
New York, NY
Donald C. Hood, PhD
James F. Bender Professor of Psychology and Professor of Ophthalmic Sciences
Columbia University
New York, NY
Thomas V. Johnson III, MD, PhD
Allan and Shelley Holt
Assistant Professor in Ophthalmology
Wilmer Eye Institute
Johns Hopkins Medicine
Baltimore, MD
Felipe Medeiros, MD, PhD
Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology
Professor, Department of Electrical and Computer Engineering
Professor, Biostatistics & Bioinformatics
Duke University School of Medicine
Durham, NC
Vincent Michael Patella, OD, FAAO
Adjunct Assistant Professor
Department of Ophthalmology
University of Iowa
Iowa City, IA
Lucy Qing Shen, MD
Director, Glaucoma Fellowship, Massachusetts Eye and Ear
Associate Professor of Ophthalmology
Harvard Medical School
Boston, MA
Janey L. Wiggs, MD, PhD
Paul Austin Chandler
Professor of Ophthalmology
Co-Director, Glaucoma Center of Excellence Vice Chair, Clinical Research
Associate Director, Ocular Genomics Institute Harvard Medical School
Associate Director, Howe Laboratory
Associate Chief
Ophthalmology Clinical Research
Senior Scientist Mass. Eye and Ear
Boston, MA
Linda Zangwill, PhD
Professor of Ophthalmology in Residence
Richard K. Lansche M.D. and Tatiana A. Lansche Endowed Chair
Co-Director of Clinical Research
Hamilton Glaucoma Center
Director, Hamilton Glaucoma Center
Data Coordinating Center
University of California, San Diego
San Diego, CA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Vincent Michael Patella, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Carl Zeiss Meditec and MI Technologies.
Lucy Qing Shen, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: AbbVie and FireCyte Therapeutics, Inc.
Murray Fingeret, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Allergan, Avellino, Bausch + Lomb, Carl Zeiss Meditec, Glaukos, Orasis Pharmaceuticals, Tarsus, Topcon, and Visus. Speaker's Bureau: Aerie Pharmaceuticals, Bausch + Lomb, Carl Zeiss Meditec, and Topcon.
Janey L. Wiggs, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Aerpio, Broadwing Bio, Editas, and Regenxbio.
Gregory K. Harmon, MD, has no financial relationships or affiliations following ineligible companies.
Linda Zangwill, PhD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: AbbVie. Grant/Research Support: Carl Zeiss Meditec, Heidelberg Engineering, Optovue, and Topcon. Owner: AISight Health.
Louis Pasquale MD, FARVO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Eyenovia, Character Biosciences, Skye Bioscience, and Twenty Twenty.
Jeffrey M. Liebmann, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Genentech, and Thea. Grant/Research Support: Novartis.
Donald C. Hood, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant and Grant/Research Support: Heidelberg Engineering, Novartis, and Topcon.
Thomas V. Johnson III, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Abbvie. Grant/Research Support: Alcon, iCare USA, InjectSense, and Perfuse Therapeutics.
Felipe Medeiros, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Novartis, Inc., Aerie, Allergan, Inc., Reichert, Inc, Carl-Zeiss, Inc., Galimedix, Inc., Biogen, Inc., Stealth BioTherapeutics, Stuart Therapeutics, Annexon, Ocular Therapeutix, and Kera Pharmaceuticals. Grant/Research Support: Novartis, Genentech, Google, Inc, and Reichert, Inc. Shareholder: Google, Inc.
Vincent Michael Patella, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Carl Zeiss Meditec and MI Technologies.
Lucy Qing Shen, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: AbbVie and FireCyte Therapeutics, Inc.
Janey L. Wiggs, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Aerpio, Broadwing Bio, Editas, and Regenxbio.
Linda Zangwill, PhD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: AbbVie. Grant/Research Support: Carl Zeiss Meditec, Heidelberg Engineering, Optovue, and Topcon. Owner: AISight Health.
The Evolve and The Glaucoma Foundation staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, the Glaucoma Foundation, AbbVie, Carl Zeiss Meditec, Glaukos, Heidelberg Engineering, New World Medical, Ora, Qlaris Bio, or Santen.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
NOTE ABOUT OBTAINING CREDIT
Learners must remain present until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 creditDeepak Sambhara, MD
